卵巢癌激素治疗进展

被引：20

作者：

郭飞

程炜

薛凤霞

李冬云

机构：

[1] 天津医科大学总医院妇科

来源：

国际妇产科学杂志 | 2011年 / 38卷 / 04期

关键词：

卵巢肿瘤; 癌; 雌激素类; 孕激素类; 雄激素类; 促性腺激素; 治疗;

D O I：

暂无

中图分类号：

R737.31 [卵巢肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

卵巢癌是病死率较高的妇科恶性肿瘤,其发病机制尚不清楚,尽管已有持续排卵假说、炎症假说、间质假说、促性腺激素假说、雄激素/孕激素假说,但无一能阐明所有卵巢癌的问题。卵巢癌的早期诊断困难,约70%的患者就诊时已是晚期,且75%在I期治疗后复发、预后差。对于复发性卵巢癌的补救化疗效果非常有限。流行病学研究及体内体外试验均已证明下丘脑-垂体-卵巢轴释放的类固醇激素可发挥刺激或抑制卵巢癌进展的作用。激素治疗对复发性卵巢癌有一定疗效且不良反应轻微。综述激素(促性腺激素释放激素、促性腺激素、雄激素、孕激素、雌激素)及其受体与卵巢癌的关系及复发性卵巢癌的激素治疗现状。

引用

收藏

页码：306 / 310

页数：5

相关论文

共 8 条

[1]

Anticancer Activity of a New Gonadotropin Releasing Hormone Analogue [J].

Saleh-Abady, Mohammad Mirzaei ;

Naderi-Manesh, Hossein ;

Alizadeh, Abdolali ;

Shamsipour, Fereshteh ;

Balalaie, Saeed ;

Arabanian, Armin .

BIOPOLYMERS, 2010, 94 (03) :292-297

[2]

Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum [J].

Ramirez, Pedro T. ;

Schmeler, Kathleen M. ;

Milam, Michael R. ;

Slomovitz, Brian M. ;

Smith, Judith A. ;

Kavanagh, John J. ;

Deavers, Michael ;

Levenback, Charles ;

Coleman, Robert L. ;

Gershenson, David M. .

GYNECOLOGIC ONCOLOGY, 2008, 110 (01) :56-59

[3]

Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells [J].

Fister, Stefanie ;

Schlotawa, Lars ;

Guenthert, Andreas R. ;

Emons, Gonter ;

Gruendker, Carsten .

GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (01) :24-29

[4]

Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion [J].

Chen, Chien-Lin ;

Cheung, Lydia W. T. ;

Lau, Man-Tat ;

Choi, Jung-Hye ;

Auersperg, Nelly ;

Wang, Hsin-Shih ;

Wong, Alice S. T. ;

Leung, Peter C. K. .

ENDOCRINE, 2007, 31 (03) :311-320

[5]

Ovarian cancer and hormone replacement therapy in the Million Women Study [J].

Beral, Valerie ;

Bull, Diana ;

Green, Jane ;

Reeves, Gillian .

LANCET, 2007, 369 (9574) :1703-1710

[6]

Gonadotropins and ovarian cancer [J].

Choi, Jung-Hye ;

Wong, Alice S. T. ;

Huang, He-Feng ;

Leung, Peter C. K. .

ENDOCRINE REVIEWS, 2007, 28 (04) :440-461

[7]

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer [J].

Verschraegen, CF ;

Westphalen, S ;

Hu, W ;

Loyer, E ;

Kudelka, A ;

Völker, P ;

Kavanagh, J ;

Steger, M ;

Schulz, KD ;

Emons, G .

GYNECOLOGIC ONCOLOGY, 2003, 90 (03) :552-559

[8]

Phase II study of mifepristone (RU486) in refractory ovarian cancer [J].

Rocereto, TF ;

Saul, HM ;

Aikins, JA ;

Paulson, J .

GYNECOLOGIC ONCOLOGY, 2000, 77 (03) :429-432